How Tumor Cells Colonize the Most Protected Organs

Immune privilege, or the capacity of specific tissues to actively limit immune responses, cannot be reduced to passive exclusion. The brain, eye, testis, and placenta each maintain this state through specialized physical barriers, resident immunosuppressive cell populations, and suppression of antigen presentation. Tumor cells metastasizing to these organs co-opt the same molecular programs that immune-privileged tissues evolved to protect themselves, turning biological safeguards into metastatic sanctuaries. The pattern points to selection rather than chance: The cells that thrive are those able to evade specialized immune programs and breach site-specific barriers. Advances in single-cell and spatial profiling, liquid biopsy, and preclinical modeling have now provided the tools to interrogate these ecosystems with previously unavailable resolution. Here, we review the biology of immune-privileged metastatic niches, advances in their detection and molecular profiling, and the therapeutic strategies emerging from this understanding, with an emphasis on molecularly guided treatment over tissue-of-origin classification.